HR 6227
118th Congress
House
Health
Cardiovascular and respiratory health
Drug safety, medical device, and laboratory regulation
Health promotion and preventive care
Prescription drugs
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 10, 2023
Referred to the Subcommittee on Health.
Nov 3, 2023
Referred to the House Committee on Energy and Commerce.
Nov 3, 2023
Introduced in House
Ask about this bill
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Plain-English summary
Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023
This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.
What's happening now
Referred to the Subcommittee on Health.
Related & companion bills
3
Bill text
1 version
- Introduced in House Formatted Text PDF Formatted XML
Committees of jurisdiction
2
Cosponsors
32
R
Fong, Vince
R
Crenshaw, Dan
R
Harshbarger, Diana
R
Balderson, Troy
Bucshon, Larry
D
Salinas, Andrea
R
Pfluger, August
R
Bice, Stephanie I.
D
Leger Fernandez, Teresa
D
Fletcher, Lizzie
D
Lee, Susie
R
Miller-Meeks, Mariannette
R
Moore, Blake D.
R
Joyce, John
D
Mullin, Kevin
D
Peters, Scott H.
R
Obernolte, Jay
D
Pettersen, Brittany
D
Stansbury, Melanie A.
Lesko, Debbie
Armstrong, Kelly
Burgess, Michael
Caraveo, Yadira
R
Ciscomani, Juan
D
Costa, Jim
R
De La Cruz, Monica
D
Gallego, Ruben
D
Levin, Mike
McCarthy, Kevin
R
Self, Keith
Steel, Michelle
R
Valadao, David G.
Cite this page
U.S. Congress. (2026). H.R. 6227: Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-HR-6227/
"H.R. 6227: Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-HR-6227/.
H.R. 6227, 118th Cong. (2026), https://openamerica.io/bill/118-HR-6227/.
[H.R. 6227: Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023](https://openamerica.io/bill/118-HR-6227/)